KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Q3 2025 value amounting to $593000.0.

  • Acadia Pharmaceuticals' Non Operating Income rose 295.14% to $593000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 115673.08%. This contributed to the annual value of -$13.7 million for FY2024, which is 36844.78% down from last year.
  • Acadia Pharmaceuticals' Non Operating Income amounted to $593000.0 in Q3 2025, which was up 295.14% from $594000.0 recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Non Operating Income peaked at $4.8 million during Q1 2023, and registered a low of -$15.0 million during Q4 2024.
  • Moreover, its 5-year median value for Non Operating Income was $481000.0 (2024), whereas its average is -$40111.1.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Non Operating Income tumbled by 37921.35% in 2022 and then soared by 132500.0% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Non Operating Income (Quarter) stood at $2.2 million in 2021, then dropped by 28.27% to $1.5 million in 2022, then fell by 2.27% to $1.5 million in 2023, then tumbled by 1092.24% to -$15.0 million in 2024, then soared by 103.96% to $593000.0 in 2025.
  • Its last three reported values are $593000.0 in Q3 2025, $594000.0 for Q2 2025, and $588000.0 during Q1 2025.